Company news
Jacobio Pharmaceuticals Group Co., Ltd. news in 2025
Jacobio Pharmaceuticals Group Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
December 21, 2025
Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
October 23, 2025
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
October 15, 2025
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
September 25, 2025
Jacobio Pharma Announces 2025 Interim Results
August 29, 2025
Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
July 2, 2025
Jacobio Pharma Announces 2024 Annual Results
March 19, 2025